An investigational treatment for myasthenia gravis, ARGX-113 (efgartigimod), being developed by the Dutch pharmaceutical firm argenx, was found to be well-tolerated and effective at improving disease symptoms as early as one week after the first infusion, trial data show. The company recently revealed top-line data from its proof-of-concept Phase 2…
Myasthenic crisis is a common complication in patients with myasthenia gravis (MG), marked by exacerbation of MG symptoms and respiratory failure. But with the rarity of MG, and its similarity to a range of other neuromuscular diseases, proper detection and treatment might fail, researchers argue. To make it easier for…
The cost of Genentech’s myasthenia gravis treatment Rituxan (rituximab) is half that of the blood purification process known as plasmapheresis and a third that of intravenous immunoglobulin therapy over a patient’s lifetime, according to a study. Few health insurance systems reimburse the costs of Rituxan for myasthenia gravis, the researchers noted.
Removing the thymus is an effective way to treat people with ocular myasthenia gravis, according to an analysis of previously published data that could resolve the controversy around the treatment. The Chinese researchers’ conclusion applied to thymectomies — or surgical removal — of thymuses that do not contain tumors. Myasthenia gravis is eliminated…
University of Southern California researchers have gained insight into how antibodies connected with a disease known as myasthenia gravis destroy a receptor crucial to movement. Their findings may give scientists clues about how to prevent the disease. The study, “Structural insights into the molecular mechanisms of…
Get regular updates to your inbox.